Brief: Surface Oncology To Present New Srf388 Clinical Data At 2022 American Society Of Clinical Oncology (Asco) Annual Meeting
27/05/2022 24:42
May 26 (Reuters) - Surface Oncology Inc SURF.O :
* SURFACE ONCOLOGY TO PRESENT NEW SRF388 CLINICAL DATA AT
2022
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
* SURFACE ONCOLOGY INC - SRF388 DEMONSTRATED CLINICAL
ACTIVITY IN
MULTIPLE SOLID TUMOR TYPES WITHTHREE CONFIRMED PARTIAL RESPONSES
ACROSS NSCLC, RCC AND HCC
* SURFACE ONCOLOGY INC - DATA SUPPORT CONTINUED EVALUATION
OF
SRF388 IN NSCLC, RCC, AND FIRST LINE HCC
* SURFACE ONCOLOGY INC - SURFACE PLANS TO INITIATE NEW
EXPANSION
STUDY OF SRF388 IN COMBINATION WITH PEMBROLIZUMAB IN
RELAPSED/REFRACTORY NSCLC
Source text for Eikon: ID:nGNX3NbRyN
Further company coverage: SURF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing